| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Emend is owned by Merck.
Emend contains Aprepitant.
Emend has a total of 1 drug patent out of which 0 drug patents have expired.
Emend was authorised for market use on 26 March, 2003.
Emend is available in capsule;oral dosage forms.
Emend can be used as prevention of postoperative nausea and vomiting; for the prevention of nausea and vomiting associated with chemotherapy.
The generics of Emend are possible to be released after 26 September, 2027.
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 26 March, 2003
Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy
Dosage: CAPSULE;ORAL
EMEND family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Emend is owned by Msd Merck Co.
Emend contains Aprepitant.
Emend has a total of 1 drug patent out of which 0 drug patents have expired.
Emend was authorised for market use on 17 December, 2015.
Emend is available in for suspension;oral dosage forms.
Emend can be used as prevention of nausea and vomiting associated with chemotherapy (cinv).
The generics of Emend are possible to be released after 26 September, 2027.
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION;ORAL
EMEND family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic